Fig. 5From: Pharmacokinetics, microscale distribution, and dosimetry of alpha-emitter-labeled anti-PD-L1 antibodies in an immune competent transgenic breast cancer modelBiodistribution of 225Ac-DOTA-anti-PD-L1-BC (15 kBq) at 1, 6, 24, 72, and 144 h in neu-N mice bearing NT2.5 tumors. 225Ac-DOTA-anti-PD-L1-BC was administered at the 3 mg/kg dose (60 μg/mouse)Back to article page